Difference between revisions of "Tamibarotene (Amnoid)"
Jump to navigation
Jump to search
m (→Also known as) |
Warner-admin (talk | contribs) m (Text replacement - "http://www.cancer.gov" to "https://www.cancer.gov") |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | From the [ | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=571791 NCI Drug Dictionary]: An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| − | + | ==History of changes in PMDA indication== | |
| + | *2005-04-11: Initial approval for the treatment of [[Acute promyelocytic leukemia]]. | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Amnoid, Amnolake | *'''Brand names:''' Amnoid, Amnolake | ||
| Line 15: | Line 16: | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
| − | [[Category:PMDA approved | + | [[Category:PMDA approved in 2005]] |
Latest revision as of 20:21, 27 June 2024
Mechanism of action
From the NCI Drug Dictionary: An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium.
Diseases for which it is used
History of changes in PMDA indication
- 2005-04-11: Initial approval for the treatment of Acute promyelocytic leukemia.
Also known as
- Brand names: Amnoid, Amnolake